



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com


www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic)



FPFT-2216

Cat. No.:	HY-145319
CAS No.:	2367619-87-0
Molecular Formula:	C ₁₂ H ₁₂ N ₄ O ₃ S
Molecular Weight:	292.31
Target:	Phosphodiesterase (PDE); Casein Kinase; Molecular Glues
Pathway:	Metabolic Enzyme/Protease; Cell Cycle/DNA Damage; Stem Cell/Wnt; PROTAC
Storage:	Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month



SOLVENT & SOLUBILITY

In Vitro	DMSO : 100 mg/mL (342.10 mM; Need ultrasonic)					
	Preparing Stock Solutions	Solvent Concentration	Mass	1 mg	5 mg	10 mg
		1 mM		3.4210 mL	17.1051 mL	34.2103 mL
		5 mM		0.6842 mL	3.4210 mL	6.8421 mL
		10 mM		0.3421 mL	1.7105 mL	3.4210 mL
Please refer to the solubility information to select the appropriate solvent.						
In Vivo	1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.5 mg/mL (8.55 mM); Clear solution					
	2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 2.5 mg/mL (8.55 mM); Clear solution					
	3. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: 2.5 mg/mL (8.55 mM); Suspended solution; Need ultrasonic					

BIOLOGICAL ACTIVITY

Description	FPFT-2216, a “molecular glue” compound, degrades phosphodiesterase 6D (PDE6D), zinc finger transcription factors Ikaros (IKZF1), Aiolos (IKZF3), and casein kinase 1α (CK1α). FPFT-2216 can be used for the research of cancer and inflammatory disease ^{[1][2]} .			
IC ₅₀ & Target	PDE6D	CK1α	IKZF1	IKZF3
In Vitro	FPFT-2216 (1 μM; 5 hours) is able to degrade PDE6D, in addition to its known targets IKZF1, IKZF3, and CK1α in MOLT4 cells ^[1]			

FPFT-2216 (1 μ M; 0 h, 2 h, 4 h, 6 h, 16 h, 24 h) shows complete degradation of PDE6D within 2 h, and the degradation of PDE6D persists for at least 24 h in MOLT4 cells^[1].

FPFT-2216 (0 nM, 1.6 nM, 8 nM, 40 nM, 200 nM, 1 μ M; 4 h) exhibits over 50% degradation of PDE6D at a dose of 8 nM, while maximum degradation of PDE6D along with IKZF1, IKZF3, and CK1 α at a dose of 200 nM in MOLT4 cells^[1].

FPFT-2216 does not impede the growth of KRAS^{G12C}-dependent MIA PaCa-2 cells^[1].

FPFT-2216 (10, 20, 40 μ M; 14 or 24 h) highly up-regulates the production of IL-2 although it is less potent than that of Pomalidomide in Naive CD4⁺ T cells^[2].

FPFT-2216 (10 μ M; 14 or 24 h) degrades IKZF1 and CK-1 α among ubiquitin-proteasomal degradative substrates of immunomodulatory drugs (IMiDs) in Naive CD4⁺ T cells^[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis^[1]

Cell Line:	MOLT4 cells
Concentration:	1 μ M
Incubation Time:	0 h, 2 h, 4 h, 6 h, 16 h, 24 h
Result:	Showed complete degradation of PDE6D within 2 h, and the degradation of PDE6D persisted for at least 24 h.

Western Blot Analysis^[1]

Cell Line:	MOLT4 cells
Concentration:	0 nM, 1.6 nM, 8 nM, 40 nM, 200 nM, 1 μ M
Incubation Time:	4 h
Result:	Exhibited over 50% degradation of PDE6D at a dose of 8 nM, while maximum degradation of PDE6D along with IKZF1, IKZF3, and CK1 α at a dose of 200 nM.

In Vivo

FPFT-2216 (30 mg/kg; p.o. or i.p.) induces significant degradation of CK-1 α , and IKZF1 in CRBN^{I391V} mice^[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	CRBN ^{I391V} mice ^[2]
Dosage:	30 mg/kg (solubilized in 0.5% carboxymethylcellulose/sodium and 0.25% Tween 80)
Administration:	p.o. or i.p.
Result:	Induced significant degradation of CK-1 α , and IKZF1.

REFERENCES

- [1]. Teng M, et al. Development of PDE6D and CK1 α Degraders through Chemical Derivatization of FPFT-2216. J Med Chem. 2022 Jan 13;65(1):747-756.
- [2]. Gemechu Y, et al. Humanized cereblon mice revealed two distinct therapeutic pathways of immunomodulatory drugs. Proc Natl Acad Sci U S A. 2018;115(46):11802-11807.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA